In today’s session Juno Therapeutics Inc (JUNO) registered an unusually high (1,137) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious JUNO increase. With 1,137 contracts traded and 9274 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: JUNO161118C00030000 closed last at: $1.6 or 18.5% up. About 514,617 shares traded hands. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 26.15% since March 15, 2016 and is downtrending. It has underperformed by 31.63% the S&P500.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on November, 8. They expect $-0.64 EPS, down 18.52% or $0.10 from last year’s $-0.54 per share. After $-0.65 actual EPS reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts -1.54% EPS growth.
Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The company was downgraded on Friday, July 8 by JP Morgan. The stock has “Equal-Weight” rating given by Barclays Capital on Wednesday, July 6. The stock has “Hold” rating given by Standpoint Research on Thursday, October 29. The firm has “Buy” rating given on Thursday, February 25 by Citigroup. The firm has “Outperform” rating given on Thursday, June 2 by Raymond James. Suntrust Robinson initiated it with “Buy” rating and $50 target price in Friday, January 29 report. FBR Capital maintained the stock with “Outperform” rating in Friday, July 8 report. The rating was initiated by Northland Capital with “Outperform” on Wednesday, July 22. The firm has “Buy” rating by Standpoint Research given on Tuesday, December 15. FBR Capital initiated Juno Therapeutics Inc (NASDAQ:JUNO) on Tuesday, August 18 with “Outperform” rating.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.26, from 1.08 in 2016Q1. The ratio increased, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Pittenger & Anderson Inc, a Nebraska-based fund reported 45 shares. Verition Fund Ltd has 0.03% invested in the company for 6,883 shares. The New York-based Morgan Stanley has invested 0.02% in Juno Therapeutics Inc (NASDAQ:JUNO). Evercore Wealth Mgmt Ltd Liability Corporation, a New York-based fund reported 18,937 shares. Ubs Asset Management Americas Inc, a Illinois-based fund reported 35,464 shares. First Tru Advisors L P holds 0.09% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 703,197 shares. Credit Suisse Ag last reported 123,916 shares in the company. California Employees Retirement Sys holds 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO) for 79,500 shares. Susquehanna Intll Group Ltd Liability Partnership last reported 0% of its portfolio in the stock. Citadel Advsrs Limited Liability last reported 0% of its portfolio in the stock. Benjamin F Edwards And Inc has invested 0.02% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). Us Financial Bank De has 90,900 shares for 0.01% of their US portfolio. Blackrock Grp Inc Limited has invested 0% of its portfolio in Juno Therapeutics Inc (NASDAQ:JUNO). State Of Wisconsin Invest Board, a Wisconsin-based fund reported 40,850 shares. Shell Asset Mgmt last reported 11,697 shares in the company.
Juno Therapeutics, Inc. is a biopharmaceutical firm focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The company has a market cap of $2.85 billion. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. It currently has negative earnings. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
JUNO Company Profile
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
More recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Prnewswire.com which released: “How These Biotech Stocks are Faring? — Biogen, Juno Therapeutics, Regeneron …” on October 18, 2016. Also Streetinsider.com published the news titled: “Form 4 Juno Therapeutics, Inc. For: Oct 05 Filed by: Klausner Richard” on October 18, 2016. Fool.com‘s news article titled: “Juno Therapeutics and Kite Pharma: The Danger of Alarmingly Thin Data” with publication date: September 21, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.